Compare Cytokinetics Inc (CYTK) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Fubotv Inc — how do they compare? Cytokinetics Inc trades at $82.38 (market cap $11.12B), while Fubotv Inc trades at $10.03 (market cap $280.89M). The key difference: Cytokinetics Inc is far larger — about 39.6× Fubotv Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | FUBO | |
|---|---|---|
Market Cap | $11.12B | $280.89M |
Sector | Technology | Technology |
52-Week High | $87.26 | $54.72 |
52-Week Low | $33.23 | $8.09 |
Enterprise Value | $11.59B | $451.31M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
FUBO trades at $9.83, up 7.08% today, with technical indicators showing neutral signals. The company reported a net loss of $172.25M in 2024, but revenue grew to $1.62B and net income is projected to turn positive in 2025. Recent CEO appointment from Disney has driven positive sentiment, while valuation ratios like P/E of 2.56 and P/S of 0.2 appear attractive relative to historical norms.
Outlook is cautiously optimistic with analyst consensus price target of $16.25 implying 65% upside, supported by streaming growth and new partnerships. Key risks include persistent cash burn and intense competition in the streaming sector. The stock offers value if profitability targets are met, but requires monitoring of subscriber trends and execution on cost controls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
